---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016467"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:28:16.283326+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership

## Summary
- Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.
- Cash, equivalents and investments $99.1M as of June 30, 2022.
- CAHmelia-203 surpassed 25% enrollment; CAHmelia-204 approaching 25% enrollment.
- Appointed P.J. Ramtin as SVP of Business Operations; two new tildacerfont method-of-use patents issued, exclusivity through 2038.
- Abstract on Phase 2a CAH data accepted for oral presentation at ICE 2022 (Aug 27).

## SEC filing metadata
- accession: 0000950170-22-016467
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/0000950170-22-016467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017022016467/sprb-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016467
- JSON: https://secwatch.observer/filing/0000950170-22-016467.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.